HAEMONETICS CORP

For the period ended Dec 30, 2023. Filed Feb 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 30, 2023 · Filed Feb 8, 2024

HAE$118.21-1.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

ITEM 1. Financial Statements

CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(Unaudited in thousands, except per share data)

	Three Months Ended		Nine Months Ended
	December 30,2023	December 31,2022	December 30,2023	December 31,2022
Net revenues	$336,250	$305,301	$965,765	$864,244
Cost of goods sold	158,383	146,594	450,123	405,396
Gross profit	177,867	158,707	515,642	458,848
Operating expenses:
Research and development	13,265	12,689	38,578	34,487
Selling, general and administrative	111,713	94,661	310,099	278,917
Amortization of acquired intangible assets	6,911	8,078	21,606	24,666
Impairment of intangible assets	—	—	10,419	—
Total operating expenses	131,889	115,428	380,702	338,070
Operating income	45,978	43,279	134,940	120,778
Interest and other expense, net	(1,949)	(1,055)	(6,489)	(12,001)
Income before provision for income taxes	44,029	42,224	128,451	108,777
Provision for income taxes	12,788	9,280	31,260	22,759
Net income	$31,241	$32,944	$97,191	$86,018
Net income per share - basic	$0.62	$0.65	$1.92	$1.69
Net income per share - diluted	$0.61	$0.64	$1.89	$1.67
Weighted average shares outstanding
Basic	50,768	50,509	50,679	50,896
Diluted	51,445	51,219	51,394	51,487
Comprehensive income	$39,564	$37,400	$103,190	$76,173

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.